BioCentury
ARTICLE | Deals

Codiak’s exosomes give Sarepta’s AAVs a tissue-targeted invisibility cloak

June 22, 2020 12:03 PM UTC

Codiak is extending its exosome platform to AAVs by partnering with Sarepta to overcome two major obstacles for nucleic acid therapies: tissue-targeting and repeat dosing.

The resulting products would be vectors within vectors, with multiple AAVs encapsulated by human cell-derived exosomes that direct them to muscle tissues while hiding them from the immune system. Once inside cells, the AAVs would mediate genomic integration of therapeutic nucleic acid cargo...